Geode Capital Management’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $293K | Sell |
47,555
-11,956
| -20% | -$71.6K | ﹤0.01% | 3792 |
|
|
2026
Q1 | $290K | Buy |
59,511
+13,432
| +29% | +$75.1K | ﹤0.01% | 3793 |
|
|
2025
Q4 | $308K | Buy |
46,079
+1,892
| +4% | +$11.2K | ﹤0.01% | 3760 |
|
|
2025
Q3 | $194K | Buy |
44,187
+185
| +0.4% | +$878 | ﹤0.01% | 3932 |
|
|
2025
Q2 | $195K | Sell |
44,002
-48,304
| -52% | -$202K | ﹤0.01% | 3884 |
|
|
2025
Q1 | $523K | Buy |
92,306
+399
| +0.4% | +$5.11K | ﹤0.01% | 3526 |
|
|
2024
Q4 | $1.94M | Buy |
91,907
+647
| +0.7% | +$14.9K | ﹤0.01% | 3140 |
|
|
2024
Q3 | $2.46M | Buy |
91,260
+1,997
| +2% | +$58.8K | ﹤0.01% | 3061 |
|
|
2024
Q2 | $2.54M | Buy |
89,263
+3,641
| +4% | +$128K | ﹤0.01% | 3049 |
|
|
2024
Q1 | $3.63M | Buy |
85,622
+5,158
| +6% | +$232K | ﹤0.01% | 2869 |
|
|
2023
Q4 | $4.31M | Buy |
80,464
+2,658
| +3% | +$120K | ﹤0.01% | 2786 |
|
|
2023
Q3 | $3.35M | Buy |
77,806
+5,333
| +7% | +$246K | ﹤0.01% | 2846 |
|
|
2023
Q2 | $3.98M | Buy |
72,473
+38,571
| +114% | +$2.12M | ﹤0.01% | 2815 |
|
|
2023
Q1 | $1.42M | Hold |
33,902
| – | – | ﹤0.01% | 3179 |
|
|
2022
Q4 | $939K | Buy |
33,902
+265
| +0.8% | +$6.53K | ﹤0.01% | 3373 |
|
|
2022
Q3 | $861K | Buy |
33,637
+68
| +0.2% | +$2.25K | ﹤0.01% | 3471 |
|
|
2022
Q2 | $1.21M | Sell |
33,569
-31,364
| -48% | -$1.42M | ﹤0.01% | 3339 |
|
|
2022
Q1 | $4.03M | Buy |
64,933
+643
| +1% | +$38K | ﹤0.01% | 2924 |
|
|
2021
Q4 | $4.53M | Buy |
64,290
+1,101
| +2% | +$78.3K | ﹤0.01% | 2946 |
|
|
2021
Q3 | $4.41M | Buy |
63,189
+1,793
| +3% | +$143K | ﹤0.01% | 2977 |
|
|
2021
Q2 | $5.11M | Buy |
61,396
+1,292
| +2% | +$91.4K | ﹤0.01% | 2891 |
|
|
2021
Q1 | $3.28M | Buy |
60,104
+5,433
| +10% | +$264K | ﹤0.01% | 2997 |
|
|
2020
Q4 | $2.35M | Buy |
54,671
+1,976
| +4% | +$73.8K | ﹤0.01% | 2997 |
|
|
2020
Q3 | $1.59M | Buy |
52,695
+630
| +1% | +$21.2K | ﹤0.01% | 3001 |
|
|
2020
Q2 | $1.61M | Buy |
52,065
+24,715
| +90% | +$666K | ﹤0.01% | 2959 |
|
|
2020
Q1 | $604K | Buy |
27,350
+66
| +0.2% | +$1.79K | ﹤0.01% | 3219 |
|
|
2019
Q4 | $832K | Buy |
27,284
+461
| +2% | +$13.3K | ﹤0.01% | 3335 |
|
|
2019
Q3 | $824K | Buy |
26,823
+3,710
| +16% | +$92.2K | ﹤0.01% | 3296 |
|
|
2019
Q2 | $462K | Sell |
23,113
-13,820
| -37% | -$405K | ﹤0.01% | 3493 |
|
|
2019
Q1 | $1.59M | Buy |
36,933
+1,650
| +5% | +$59.8K | ﹤0.01% | 2979 |
|
|
2018
Q4 | $1.12M | Buy |
35,283
+1,838
| +5% | +$72.5K | ﹤0.01% | 3062 |
|
|
2018
Q3 | $1.75M | Buy |
33,445
+6,117
| +22% | +$343K | ﹤0.01% | 2956 |
|
|
2018
Q2 | $1.46M | Buy |
27,328
+12,649
| +86% | +$648K | ﹤0.01% | 3021 |
|
|
2018
Q1 | $733K | Hold |
14,679
| – | – | ﹤0.01% | 3264 |
|
|
2017
Q4 | $484K | Hold |
14,679
| – | – | ﹤0.01% | 3369 |
|
|
2017
Q3 | $550K | Hold |
14,679
| – | – | ﹤0.01% | 3325 |
|
|
2017
Q2 | $374K | Sell |
14,679
-581
| -4% | -$14.4K | ﹤0.01% | 3453 |
|
|
2017
Q1 | $396K | Buy |
15,260
+666
| +5% | +$19.2K | ﹤0.01% | 3394 |
|
|
2016
Q4 | $445K | Buy |
14,594
+53
| +0.4% | +$1.35K | ﹤0.01% | 3308 |
|
|
2016
Q3 | $395K | Buy |
14,541
+1,408
| +11% | +$39.1K | ﹤0.01% | 3344 |
|
|
2016
Q2 | $375K | Sell |
13,133
-3,730
| -22% | -$119K | ﹤0.01% | 3338 |
|
|
2016
Q1 | $509 | Buy |
16,863
+225
| +1% | +$6.38K | ﹤0.01% | 3232 |
|
|
2015
Q4 | $577K | Buy |
16,638
+26
| +0.2% | +$889 | ﹤0.01% | 3202 |
|
|
2015
Q3 | $627K | Buy |
16,612
+1,563
| +10% | +$72.7K | ﹤0.01% | 3112 |
|
|
2015
Q2 | $857K | Buy |
15,049
+1,314
| +10% | +$74.8K | ﹤0.01% | 2976 |
|
|
2015
Q1 | $798K | Sell |
13,735
-3,302
| -19% | -$177K | ﹤0.01% | 2985 |
|
|
2014
Q4 | $965K | Sell |
17,037
-80
| -0.5% | -$3.81K | ﹤0.01% | 2868 |
|
|
2014
Q3 | $699K | Buy |
17,117
+684
| +4% | +$31.5K | ﹤0.01% | 2994 |
|
|
2014
Q2 | $747K | Buy |
16,433
+3,944
| +32% | +$166K | ﹤0.01% | 2974 |
|
|
2014
Q1 | $591K | Buy |
12,489
+3,443
| +38% | +$157K | ﹤0.01% | 3072 |
|
|
2013
Q4 | $425K | Sell |
9,046
-2,636
| -23% | -$115K | ﹤0.01% | 3149 |
|
|
2013
Q3 | $466K | Buy |
11,682
+493
| +4% | +$19.4K | ﹤0.01% | 2988 |
|
|
2013
Q2 | $401K | Buy |
+11,189
| New | +$428K | ﹤0.01% | 2976 |
|
Other funds holding HBIO
WCM
MIM
NCNMGF
CCM
MBAM
Geode Capital Management's HBIO Position: Q2 2026 in Review
Geode Capital Management reduced its Harvard Bioscience (HBIO) stake by 20% in Q2 2026, selling an estimated $71.6K and leaving 47,555 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #3792.
Geode Capital Management first reported a position in HBIO in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.11M in Q2 2021. 34 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.
- Geode Capital Management held 47,555 shares of Harvard Bioscience worth $293K as of Q2 2026.
- Geode Capital Management sold 11,956 Harvard Bioscience shares in Q2 2026, an estimated $71.6K.
- Harvard Bioscience made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3792 holding.
- Geode Capital Management first reported a position in Harvard Bioscience in Q2 2013 and has held it in 53 quarters since.
- Geode Capital Management's Harvard Bioscience position peaked at $5.11M in Q2 2021.
- 34 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.